Pacific Edge rewarded for surging stock with entry to NZX 50 as Hallenstein leaves

Pacific Edge rewarded for surging stock with entry to NZX 50 as Hallenstein leaves
By Suze Metherell March 13 (BusinessDesk) – Pacific Edge, the bladder cancer test developer whose shares have soared in the past year, will join the NZX 50 Index this month, replacing retailer Hallenstein Glasson Holdings, whose stock has tumbled in the same period. Hallenstein’s share price has declined 44 percent in the past 12 months while Pacific Edge has surged 118 percent, outpacing the benchmark index’s 17 percent rise. Pacific Edge’s market cap has grown to $445.1 million while Hallenstein’s is at about $184 million. Shares of Paci...